Moderators: Helen MacKay, MD and David Miller, MD 

Presentations:

• (LBA) Durvalumab + carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for endometrial cancer (EC) (DUO-E/GOG-3041/ENGOT-EN10): Objective response rate (ORR) and duration of response (DoR) by mismatch repair status (Hye Sook Chon, MD)
• (LBA) Durvalumab + carboplatin/paclitaxel followed by durvalumab ± olaparib as a first‑line treatment for endometrial cancer: overall survival and additional secondary efficacy endpoints by mismatch repair (MMR) status in the DUO-E/GOG-3041/ENGOT-EN10 trial (Jean-François Baurain, MD)
• DUO-E Patient Perspective (Jan Bush)
• (LBA) A Phase II, randomized, double-blind, study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer (Bradley R. Corr, MD)
• (LBA) Lenvatinib Plus Pembrolizumab Versus Chemotherapy As First-Line Therapy For Advanced Or Recurrent Endometrial Cancer: Primary Results Of The Phase 3 ENGOT-En9/LEAP-001 Study (Christian Marth, MD, PhD)
• (LBA) Overall Survival in Patients in GOG-0258 by Molecular Classification with a Modified Promise Algorithm: Ancillary Analysis of GOG-0258 (Aine E. Clements, MD)
• Distillation: Robert Coleman, MD 
• (LBA) Durvalumab + paclitaxel/carboplatin + bevacizumab followed by durvalumab, bevacizumab + olaparib maintenance among patients with newly diagnosed advanced ovarian cancer without a tumor BRCA1/BRCA2 mutation: updated results from DUO-O/ENGOT-ov46/GOG-3025 trial (Philipp Harter, MD, PhD)
• (LBA) Overall survival with camrelizumab plus famitinib versus camrelizumab alone and investigator's choice of chemotherapy for recurrent or metastatic cervical cancer (Xiaohua Wu, MD)
• (LBA) Phase 1 Analysis from the PYNNACLE Phase 1/2 Study of PC14586 in the Subgroup of Patients with Advanced Ovarian Cancer Harboring a TP53 Y220C Mutation (Alison Schram, MD)
• Distillation: Making the most of Biomarkers in Ovarian Cancer (Jonathan Ledermann, MD)